Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of CPP-EDG 01 study is to assess possible genetic and/or environmental parameters which may influence the growth rate of children affected by precocious puberty. In this view, we are collecting clinical data and biological samples of children attended as outpatients at the Pediatric Endocrine Center of Pisa from 1998 to present (the study is still open). From biological (blood) samples, gene polymorphisms such as endocrine disruptor levels are determined and compared to different growth pattern of pediatric patients treated with different GnRH agonists.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Psychosocial Impact of Early Puberty in Girls Aged 6 to 8 Years

NCT01679925

Early Puberty

COMPLETED

Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty

NCT02920515

Central Precocious Puberty

COMPLETED PHASE4

A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants

NCT02427958

Central Precocious Puberty

COMPLETED PHASE4

Long-term Outcome of GnRH Analogues Treatment of Children With Idiopathic Central Precocious Puberty

NCT02790112

Puberty, Precocious Adiposity

UNKNOWN NA

Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation

NCT01073605

Growth Disorders Intrauterine Growth Retardation

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Precocious Puberty

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Triptorelin (GnRH agonists)

Intervention Type DRUG

Leuprolide (GnRH agonists)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinica diagnosis of central precocious puberty
* Diagnosis is based on growth spurt, bone age advancement, positive GnRH agonist stimulating test, pubertal sex steroid levels before 8 years of age for female and 9 years for male, respectively